A5032212361- Systemic Lupus Erythematosus Research
- SARS-CoV-2 and COVID-19 Research
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Systemic Sclerosis and Related Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Autoimmune and Inflammatory Disorders Research
- COVID-19 Clinical Research Studies
- Dermatological and COVID-19 studies
- Herpesvirus Infections and Treatments
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Diabetes and associated disorders
- Renal Diseases and Glomerulopathies
- Vasculitis and related conditions
- Liver Diseases and Immunity
- Atherosclerosis and Cardiovascular Diseases
- Pharmaceutical studies and practices
- Ocular Diseases and Behçet’s Syndrome
- Salivary Gland Disorders and Functions
- Intramuscular injections and effects
- Inflammatory Myopathies and Dermatomyositis
- Neurological and metabolic disorders
- Cytomegalovirus and herpesvirus research
- Spondyloarthritis Studies and Treatments
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2017-2025
Universidade de São Paulo
2020-2024
Universidade Nove de Julho
2024
Center for Rheumatology
2021-2022
Objective To evaluate the effect on immunogenicity and safety of 2-week methotrexate (MTX) discontinuation after each dose Sinovac-CoronaVac vaccine versus MTX maintenance in patients with rheumatoid arthritis (RA). Methods This was a single-centre, prospective, randomised, investigator-blinded, intervention study ( NCT04754698 , CoronavRheum) including adult RA (stable Clinical Disease Activity Index (CDAI) ≤10, prednisone ≤7.5 mg/day) randomised (1:1) to withdraw (MTX-hold) for 2 weeks or...
Objective To determine the immunogenicity of third dose CoronaVac vaccine in a large population patients with autoimmune rheumatic diseases (ARD) and factors associated impaired response. Methods Adult ARD age-balanced/sex-balanced controls (control group, CG) previously vaccinated two doses received at D210 (6 months after second dose). The presence anti-SARS-CoV-2 S1/S2 IgG neutralising antibodies (NAb) was evaluated to vaccination (D210) 30 days later (D240). Patients controlled disease...
To date, the only study that has assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but sample size precluded an accurate analysis of effect individual drugs. Therefore, we evaluated immunogenicity inactivated SARS-CoV-2 (Sinovac-CoronaVac) and influence different medications SLE. Safety was also assessed.We conducted prospective controlled 232 SARS-CoV-2-naive SLE patients 58 controls who...
Objectives To evaluate the distinct impact of disease modifying antirheumatic drugs (DMARD) combination and monotherapy in immune response to an inactivated SARS-CoV-2 vaccine patients with rheumatoid arthritis (RA). Methods This phase 4 prospective study analysed seroconversion (SC) anti-SARS-CoV-2 immunoglobulin G (IgG) neutralising antibodies (NAb) induced by (CoronaVac) RA comparison controls (CG). Disease activity treatment were also assessed. Only participants baseline negative IgG/NAb...
We aimed to examine the immunogenicity pattern induced by inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Life Sciences, Beijing, China) in seropositive patients with autoimmune rheumatic diseases compared controls, seronegative diseases, and controls.
Abstract Objectives To assess immunogenicity of a heterologous fourth dose an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated (Sinovac-CoronaVac). Methods A total 164 ARD who were disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies—NAb) the third Sinovac-CoronaVac received additional 3 months after last dose. and...
Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency antiphospholipid antibodies (aPL). Recent reports thrombosis associated adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production PAPS patients, after vaccinating Sinovac-CoronaVac, inactivated virus vaccine against COVID-19.This prospective...
Aim: The use of anti-TNF drugs is well-established for treating axial spondyloarthritis (axSpA). introduction biosimilars offers a more accessible alternative, but data on the switching adalimumab in axSpA population remain somewhat controversial and are limited to SB5 ABP 501 European population. This study aims evaluate clinical efficacy from originator biosimilar adalimumab-AACF Latin American patients over 12-month period real-life analysis. Methods: observational included with who had...
Background Systemic lupus erythematosus (SLE) increases the risk of ischemic stroke (IS) and cerebral small vessel disease (CSVD) through a unique interplay cardiovascular immune-mediated mechanisms. There is an unmet need predictors IS characterization distinctive features CSVD in patients with SLE. Objectives To assess if more extensive SLE (IS+) than those without (IS-); to identify neuroimaging Methods This observational study, conducted at academic referral center São Paulo, Brazil,...
Patients with autoimmune rheumatic diseases (ARDs) are at an increased risk for herpes zoster (HZ). Vaccination is recommended this population. The aim of study was to evaluate the safety vaccination recombinant vaccine (Shingrix) in ARD patients, humoral immunogenicity (HI), cellular (CI), and incidence HZ. This randomized, double-blind, placebo-controlled phase 4 involves 1180 patients a control group (CG) 393 balanced healthy individuals, aged ≥50 years. will be randomly assigned blinded...
A obesidade, doença crônica não transmissível, caracterizada pelo acúmulo de tecido adiposo a ponto comprometer saúde do indivíduo, presente em menores idade, que comumente pode estar vinculado à Hipertensão Arterial Sistêmica (HAS). Objetiva-se através desse estudo identificar relação da obesidade adolescentes, com HAS, por meio Programa Saúde na Escola (PSE). Nesse contexto, os estudantes medicina UNIP São José Rio Pardo, baseados literatura, desenvolveram e aplicaram um questionário,...
O014 / #382 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes ABSTRACT CONCURRENT SESSION 02: SLE METRICS – IMPROVING OUTCOMES MEASURES 22-05-2025 1:40 PM 2:40 Background/Purpose Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease of unknown etiology. Diagnosis often delayed because it frequently mimics symptoms other diseases; this also delays treatment initiation. Previous studies have reported that delay in diagnosis was associated with worse prognosis...
PT005 / #801 Topic: AS17 - Miscellaneous POSTER TOUR 01: CLINICAL OUTCOMES IN SLE 22-05-2025 10:00 AM 10:40 Background/Purpose Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) and the new recombinant vaccine against HZ (RZV) offers safety improvements. This study evaluates disease safety, overall humoral immunogenicity RZV in ARD patients compared to nonvaccinated ARDs nonimmunosuppressed control group (CG). Methods prospective double-blind randomized...
Objectives It is unknown if hydroxychloroquine blood level dynamics impact flare rates in lupus nephritis patients. We prospectively evaluated levels to determine which blood-based patterns are more associated with disease activity. Methods In total, 82 patients under a prescribed dose of 4–5.5 mg/kg actual body weight (maximum 400 mg/day) for ≥3 months were at baseline and 7 months. Hydroxychloroquine determined by liquid chromatography-tandem mass spectrometry. Flare was defined as...
To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) the possible influence baseline disease parameters, comorbidities therapy on immune response.This prospective controlled study included 53 patients with SAMs 106 non-immunocompromised control group (CTRL). All participants received two doses Sinovac-CoronaVac (28-day interval). Immunogenicity was assessed by anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC), anti-S1/S2 geometric...
Abstract Objective To review current literature to support the use of mesna as a preventive therapy for hemorrhagic cystitis and bladder cancer in patients with systemic autoimmune diseases vasculitis treated cyclophosphamide. Materials methods The search articles was conducted systematically through MEDLINE, LILACS, Cochrane Library, Embase databases. Only English were selected. For available records, titles abstracts selected independently by two investigators. Results Eighteen studies...
Abstract Objective To analyse the safety, immunogenicity and factors affecting antibody response to Severe Acute Respiratory Syndrome–Coronavirus–2 (SARS-CoV-2) vaccination in patients with SSc. Methods This is a phase 4 prospective study within larger trial of two doses inactivated SARS-CoV-2 vaccine (CoronaVac) 51 SSc compared 153 controls. Anti-SARS-CoV-2-IgG neutralizing antibodies (NAb) were assessed at each shot (D0/D28) 6 weeks after second dose(D69), only individuals negative...
CONCLUSIONCoronaVac has an excellent safety profile and induces moderate IgG seroconversion neutralizing antibodies in the majority of patients with ARD.